Sunday 18 October 2026
Export VYGR’s income statement to Excel — free account
Voyager Therapeutics, Inc.
VYGR Healthcare Biotechnology
Voyager Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.4 million, down 49.5% from fiscal 2024. In the quarter to June 2026, revenue fell 39.1%, EPS grew 29.8% and free cash flow grew 24.8%, each against the same quarter a year earlier.
1.90
0.16
−7.77%
Follow VYGR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
8.77 | 5.71 | 6.29 | 6.15 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(8.84) | (7.62) | (6.87) | (8.20) | |
P/B ratio |
1.25 | 1.18 | 1.32 | 1.37 | |
Price to Tangible BV |
1.25 | 1.18 | 1.32 | 1.37 | |
EV/Sales |
2.10 | 0.85 | 2.42 | 2.77 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.56) | (0.26) | (0.69) | (0.79) | |
EV/FCF |
(0.55) | (0.25) | (0.68) | (0.79) | |
Quick Ratio |
6.00 | 7.47 | 8.20 | 7.16 | |
Current Ratio |
6.19 | 7.64 | 8.42 | 7.51 | |
Net Debt/EBITDA |
6.89 | 6.68 | 4.76 | 4.52 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.09 | 0.13 | 0.13 | 0.13 | |
Operating CF/Net income |
1.11 | 1.10 | 1.20 | 1.06 | |
Capex/Depreciation |
(0.74) | (1.21) | (0.02) | 0.00 | |
Research and Development Expense of Revenue |
268.36% | 234.43% | 948.79% | 696.40% | |
Selling, General and Administrative Expense of Revenue |
60.55% | 60.75% | 318.59% | 237.47% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
25.89% | 22.96% | 95.95% | 76.87% | |
Graham Net Nets |
0.55 | 0.64 | 0.44 | 0.39 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(46.25%) | (51.91%) | (51.30%) | (51.71%) | |
Free Cash Flow Yield |
(43.28%) | (58.56%) | (56.58%) | (57.30%) | |
Revenue per Share |
0.23 | 0.26 | 0.04 | 0.05 | |
Operating CF per Share |
(0.53) | (0.52) | (0.56) | (0.43) | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.53) | (0.53) | (0.56) | (0.43) | |
Cash per Share |
3.55 | 3.35 | 2.38 | 1.92 | |
Shareholders Equity per Share |
3.74 | 3.34 | 2.92 | 2.55 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.74 | 3.34 | 2.92 | 2.55 | |
Free Cash Flow |
(31.25) | (30.89) | (33.43) | (25.84) | |
Working Capital |
184.09 | 176.15 | 129.53 | 108.54 | |
Capital Expenditures |
(0.21) | (0.63) | (0.01) | 0.00 | |
Net Current Asset Value |
151.10 | 146.49 | 101.33 | 81.85 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.04 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
11.85 | 2.05 | 1.88 | 2.84 | |
Average Payables |
2.64 | 4.50 | 2.68 | 1.71 | |
Average Assets |
357.18 | 322.67 | 286.28 | 259.93 | |
Average Common Equity |
275.07 | 247.92 | 223.19 | 199.16 |
Columns are period end dates